Insights from the FLOW Trial | ESC 2024

JACC This Week
30/08/2024 10 min
Insights from the FLOW Trial | ESC 2024

Listen "Insights from the FLOW Trial | ESC 2024"

Descargar episodio Ver en sitio original

Episode Synopsis

Neha J. Pagidipati, MD, FACC, JACC Associate Editor, and Richard Pratley, MD, discuss insights from the FLOW trial – revealing that semaglutide reduced heart failure events and cardiovascular death by approximately 27%, both in patients with and without prior heart failure.

More episodes of the podcast JACC This Week

December 2, 2025: Global CVD 1990–2023: Trends, Risks, and the Road Ahead | JACC This Week 24/11/2025
November 25, 2025: Clonal Hematopoiesis, Alcohol and Blood Pressure, Long-Term Risk, and Emerging Biomarkers | JACC This Week 17/11/2025
November 18, 2025: Adiposity, Heart Failure, and the Future of Cardiometabolic Care | JACC This Week 10/11/2025
November 11, 2025: Precision, Place, and the Future of Cardiovascular Prediction | JACC This Week 03/11/2025
November 4, 2025: The 2025 Hypertension Guideline: A New Era in Blood Pressure Control | JACC This Week 28/10/2025
October 28.2025: How Low Should We Go? | JACC This Week 20/10/2025
October 21, 2025 - The Adipokine Hypothesis, Adipose-Cardiac Signaling, Sex Differences, Therapeutic Implications, and Diverse Populations | JACC This Week 13/10/2025
October 14, 2025 - Emerging Frontiers in Cardiovascular Medicine: From Certification Reform to Inflammation Targeting | JACC This Week 06/10/2025
October 7, 2025: AI in Scientific Writing and New Frontiers in Cardiovascular Care | JACC This Week 29/09/2025
Computable Quality, Community Screening, and TAVR Debate | JACC This Week 29/09/2025
© 2003-2025 ZARZA | AHEAD OF OUR TIME
privacy policy
In God we trust In God we trust
PreSales Questions? Click Here
or call our toll-free line at +1-888-5002068 Miami, Florida, USA